Tommy Alfaro Moya(@tomam04) 's Twitter Profile Photo

Our colleague Niranjan Khaire presenting the joint proposal regarding the outcomes of patients with aplastic anemia lacking a MSD undergoing alloHCT with PTCY as GVHD prophylaxis
Hans Messner Allogeneic BMT Program Moffitt Cancer Center

Our colleague @niranjankhaire presenting the joint proposal regarding the outcomes of patients with aplastic anemia lacking a MSD undergoing alloHCT with PTCY as GVHD prophylaxis
@Hans_BMTProgram @MoffittNews #Tandem24
account_circle
James Davis, PharmD, BCOP(@thisisJamesD) 's Twitter Profile Photo

Because my United Airlines flight was delayed >8hr and I will be missing the poster session, I will be presenting my poster virtually from the airport 😂 from now until departure. We investigated frailty instead of age for patients undergoing CAR T for MM. results below…

Because my @united flight was delayed >8hr and I will be missing the poster session, I will be presenting my #Tandem24 poster virtually from the airport 😂 from now until departure. We investigated frailty instead of age for patients undergoing CAR T for MM. results below…
account_circle
Alexandra Gomez A.(@AGomez_MD) 's Twitter Profile Photo

A Prospective Study of Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation, as a Potential Alternative to Anti-Thymocyte Globulin
Nina Orfali Mohammad Alhomoud Weill Cornell Medicine Weill Cornell MedicineBMT

A Prospective Study of Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation, as a Potential Alternative to Anti-Thymocyte Globulin
@NinaOrfali @moh7madhomod @WeillCornell @WeillCornellBMT #Tandem24
account_circle
Actinium Pharma(@ActiniumPharma) 's Twitter Profile Photo

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active R/R AML in the Phase 3 SIERRA Trial at the Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Read: bit.ly/3wCgfw2 $ATNM

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active R/R AML in the Phase 3 SIERRA Trial at the #Tandem24 Meetings | Transplantation & Cellular Therapy Meetings of @ASTCT and @CIBMTR. Read: bit.ly/3wCgfw2 $ATNM
account_circle